Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Endocrinology | US/EU | 2017

Login to access report north_east
Contact sales account_box

Recent launches of Merck & Co.’s Lusduna (insulin glargine) in Europe, and Eli Lilly/Boehringer Ingelheim’s Basaglar (insulin glargine) in the United States, have expanded the non-innovator sector of the endocrinology market. Uptake of these products, as well as that of competing insulins and human growth hormone biologics including Omnitrope and Genotropin, will depend on the prescribing behavior of endocrinologists. For this reason, it is critical that manufacturers/marketers of insulin and somatropin biosimilars and brands understand which factors influence endocrinologists’ opinions, actions, and expectations. To this end, Decision Resources Group conducted primary market research with endocrinologists in France, Germany, and the United States.

Questions answered:

  • Have endocrinologists received recommendations to use biosimilars?
  • Are endocrinologists switching patients from reference brands to biosimilars?
  • What factors do endocrinologists consider when choosing among competing biosimilars?
  • How are insulin biosimilars and Omnitrope performing, and what are endocrinologists’ expectations for their future uptake?
  • What are the key drivers and barriers to uptake of insulin and somatropin biosimilars?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Boehringer Ingelheim
  • Eli Lilly
  • Merck & Co.
  • Novo Nordisk
  • Sanofi

Key drugs mentioned:

  • Apidra
  • Basaglar/Abasaglar
  • Genotropin
  • Humalog
  • Humatrope
  • Lantus
  • Levemir
  • Lusduna Nexvue/Lusduna
  • Norditropin
  • NovoLog/NovoRapid
  • Nutropin
  • Omnitrope
  • Saizen
  • Toujeo
  • Tresiba
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
north_east
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east